Orthobiologics company OrthoSera GmbH said today it won CE Mark approval in the European Union for its hypACT system designed to aid in regenerating osteoarthritic bone. The Austrian company’s hypACT device is designed to deliver its hyperacute, platelet rich plasma serum to aid in regeneration for patients with osteoarthritis and other degenerative diseases. “After the […]
Regulatory/Compliance
FDA draft guidance on 510(k)s omits combination devices
Combination medical devices which bring together device components and drugs or biological products into a single unit are missing from new draft guidance from the FDA. The guidance, released last week, covered recommendations for manufacturers on when to submit 510(k) applications for modifications to devices currently on the market, replacing guidance that was 19 years […]
Intersect ENT files with FDA for drug-delivering sinus implant
Intersect ENT (NSDQ:XENT) said today it submitted a supplemental premarket approval submission to the FDA seeking approval for a new Nova steroid releasing implant for treating patients with chronic sinus disease. The new Nova device is designed with a lower profile to allow for placement in smaller sinus openings, and will expand the usable patient population for […]
QT Vascular wins CE Mark for Chocolate Heart DCB
QT Vascular said today that it won CE Mark approval in the European Union for its Chocolate Heart drug-coated balloon for treating coronary artery disease. The Chocolate Heart device is a paclitaxel-coated version of the Chocolate balloon that won FDA approval back in June 2014, the Singapore-based company said. “We are delighted with the CE […]